1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Durable response to brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) in a patient with CD30-positive PTCL arising as a post-transplant lymphoproliferative disorder (PTLD)
    Journal Article

    Hong, J.; Johnson, W. T.; Kartan, S.; Gonsalves, A. S.; Fenkel, J. M.; Gong, J. Z.; Porcu, P.
    Current Oncology (2021)

    Fulltext@MSK | Save
  • Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: An analysis of the INVICTUS Study
    Journal Article

    Zalcberg, J. R.; Heinrich, M. C.; George, S.; Bauer, S.; Schöffski, P.; Serrano, C.; Gelderblom, H.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    The Oncologist (2021)

    Fulltext@MSK | Save
  • Temozolomide in grade 3 gastroenteropancreatic neuroendocrine neoplasms: A multicenter retrospective review
    Journal Article

    Chan, D. L.; Bergsland, E. K.; Chan, J. A.; Gadgil, R.; Halfdanarson, T. R.; Hornbacker, K.; Kelly, V.; Kunz, P. L.; McGarrah, P. W.; Raj, N. P.; more...
    The Oncologist (2021)

    Fulltext@MSK | Save
  • Feasibility of combining the phosphatidylinositol 3-kinase inhibitor copanlisib with rituximab-based immunochemotherapy in patients with relapsed indolent B-cell lymphoma
    Journal Article

    Matasar, M. J.; Dreyling, M.; Leppä, S.; Santoro, A.; Pedersen, M.; Buvaylo, V.; Fletcher, M.; Childs, B. H.; Zinzani, P. L.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study
    Journal Article

    Javle, M.; Roychowdhury, S.; Kelley, R. K.; Sadeghi, S.; Macarulla, T.; Weiss, K. H.; Waldschmidt, D. T.; Goyal, L.; Borbath, I.; El-Khoueiry, A.; more...
    The Lancet Gastroenterology & Hepatology (2021)

    Fulltext@MSK | Save
  • Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study
    Journal Article

    Javle, M.; Borad, M. J.; Azad, N. S.; Kurzrock, R.; Abou-Alfa, G. K.; George, B.; Hainsworth, J.; Meric-Bernstam, F.; Swanton, C.; Sweeney, C. J.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer
    Journal Article

    Kyi, C.; Doubrovina, E.; Zhou, Q.; Kravetz, S.; Iasonos, A.; Aghajanian, C.; Sabbatini, P.; Spriggs, D.; O'Reilly, R. J.; O'Cearbhaill, R. E.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study
    Editorial

    Modi, S.
    Future Oncology (2021)

    Fulltext@MSK | Save
  • Pseudoaneurysm within a desmoid tumor in an extremity: Report of 2 cases
    Journal Article

    Long, N. M.; Gounder, M. M.; Crago, A. M.; Chou, A. J.; Panicek, D. M.
    Skeletal Radiology (2021)

    Fulltext@MSK | Save
  • CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): An open-label dose-finding and first-in-human study
    Journal Article

    Naing, A.; Thistlethwaite, F.; de Vries, E. G. E.; Eskens, F. A. L. M.; Uboha, N.; Ott, P. A.; LoRusso, P.; Garcia-Corbacho, J.; Boni, V.; Bendell, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save